BioNTech and OncoC4 Initiate Pivotal Phase 3 Trial of BNT316/ONC-392 Program in Metastatic NSCLC

BioNTech SE announced that the first patient with NSCLC has been treated in a pivotal Phase III trial evaluating the companies’ next-generation anti-CTLA-4 antibody candidate BNT316/ONC-392.